




Parafibromin, Product of the Hyperparathyroidism-Jaw Tumor Syndrome Gene HRPT2
Takeo IWATA
Abstract：Primary hyperparathyroidism is characterized by the calcium-insensitive hypersecretion of 
parathyroid hormone and formation of parathyroid tumors. The disease usually results from a single 
parathyroid adenoma, but in a minority of cases is a part of hereditary syndromes; multiple endocrine 
neoplasia types 1 and 2A, familial isolated hyperparathyroidism, and hyperparathyroidism-jaw tumor 
(HPT-JT) syndrome. HPT-JT syndrome is characterized by parathyroid tumors, fibro-osseous lesions 
of the mandible and maxilla, and renal cysts and tumors. The gene whose inactivation is directly 
associated with the pathogenesis of HPT-JT syndrome has been identified as the tumor suppressor 
gene HRPT2. Parafibromin, a 531-amino acid protein encoded by HRPT2, has partial homology with 
the yeast Cdc73, a component of the RNA polymerase II-associated Paf1 complex including Paf1, 
Leo1, Ctr9, and Rtf1. Parafibromin binds to RNA polymerase II as a part of human Paf1 complex 
together with human orthologs of Paf1, Leo1, Ctr9. Human Paf1 complex appears to be involved in 
transcription elongation. Parafibromin has antiproliferative activity by inhibition of cyclin D1 and 
c-myc proto-oncoprotein. Whereas, we recently demonstrated that parafibromin acts as a positive 
regulator of cell growth like an oncoprotein in the presence of SV40 large T antigen, indicating 
parafibroimin has potentially ambivalent functions in tumorigenesis. This review focuses on the 
functions of parafibromin and human Paf1 complex, providing an insight into its potential involvement 
in the development of cancer.
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hyperparathyroidism；FIHP），多発性内分泌腫瘍症１型



















JTの原因遺伝子は 1q25-q31 に位置する HRPT2 であり，
これまでに HPT-JT家系の約半数において HRPT2 の不
活性化を伴う胚細胞変異が認められている7-12）。また散
発性の副甲状腺癌でも HRPT2 の体細胞変異が認められ


















　パラフィブロミンの C末端側は酵母の Cdc73 と相

























ヒト Paf1 複合体を形成していると考えられる。Rtf1 の
ヒトホモログも存在するが，ヒト Paf1複合体中でその
結合は弱い。その代わりにヒト Paf1 複合体には hSki8 













転写複合体にヒト Paf1複合体と RNF20/40 と UbcH6 を
含む H2Bユビキチン化複合体をリクルートする。ヒト









Ctr9 ホモログの発現抑制細胞では H3K4 のモノメチル化
およびトリメチル化と H3K79 のジメチル化が抑制され
ることが報告されている35）。
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　我々はパラフィブロミンを HEK293 や NIH3T3 細胞
株に過剰発現させると細胞増殖が抑制されるが，SV40 
large T抗原（LT）発現細胞株である 293FTや COS7 の
細胞株では逆にパラフィブロミン過剰発現は細胞増殖
を促進することを見出した39）。パラフィブロミンの過剰


































ロミンの発現抑制がサイクリン D1 や c-mycの発現を促
進するという前述の報告と矛盾するものである。この矛
盾を解決できる報告は現在のところなされていない。ま

















が促進され，H19（H19 fetal liver mRNA），Igf1 （insulin-
like growth factor 1），Igf2 （Insulin-like growth factor 
2），Igfbp4 （Insulin-like growth factor binding protein 4），
Hmgcs2 （3-hydroxy-3-methyl-glutaryl-coenzyme A synthase 
2），Hmga1 （high-mobility group AT-hook 1），Hmga2
（high-mobility group AT-hook 2）の成長因子遺伝子群の
発現減少が認められる。これらの遺伝子のプロモーター
上にパラフィブロミンおよび Paf1 複合体の結合が認め






















１） Grimelius L and Johansson H: Pathology of parathyroid 
tumors. Semin Surg Oncol 13, 142-154 (1997)
２） Marx SJ: Molecular genetics of multiple endocrine 
neoplasia types 1 and 2. Nat Rev Cancer 5, 367-375 
(2005)
３） Brown EM and MacLeod RJ: Extracellular calcium 
sensing and extracellular calcium signaling. Physiol Rev 
81, 239-297 (2001)
４） Chen CD, Morrison C, Zhang C, Kahnoski K, Carpten ID 
and Teh BT:  Hyperparathyroidism-jaw tumor syndrome. 
J Intern Med 253, 634-642 (2003)
５） Simonds WF, James-Newton LA, Agarwal SK, Yang B, 
Skarulis MC, Hendy GN and Marx SJ: Familial isolated 
hyperparathyroidism: clinical and genetic characteristics 
of 36 kindreds. Medicine 81, 1-26 (2002)
６） Bradley KJ, Hobbs MR, Buley ID, Carpten JD, Cavaco 
BM, Fares JE, Laidler P, Manek S, Robbins CM, Salti 
IS, Thompson NW, Jackson CE and Thakker RV: 
Uterine tumours are a phenotypic manifestation of the 
hyperparathyroidism-jaw tumour syndrome. J Intern Med 
257, 18-26 (2005) 
７） Carpten JD, Robbins CM, Villablanca A, Forsberg L, 
Presciuttini S, Bailey-Wilson J, Simonds WF, Gillanders 
EM, Kennedy AM, Chen JD, Agarwal SK, Sood R, 
Jones MP, Moses TY, Haven C, Petillo D, Leotlela PD, 
Harding B, Cameron D, Pannett AA, Höög A, Heath H 
3rd, James-Newton LA, Robinson B, Zarbo RJ, Cavaco 
BM, Wassif W, Perrier ND, Rosen IB, Kristoffersson 
U, Turnpenny PD, Farnebo LO, Besser GM, Jackson 
CE, Morreau H, Trent JM, Thakker RV, Marx SJ, Teh 
BT, Larsson C and Hobbs MR: HRPT2, encoding 
parafibromin, is mutated in hyperparathyroidism-jaw 
tumor syndrome. Nat Genet 32, 676-680 (2002)
８） Howell VM, Haven CJ, Kahnoski K, Khoo SK, Petillo 
D, Chen J, Fleuren GJ, Robinson BG, Delbridge LW, 
Philips J, Nelson AE, Krause U, Hammje K, Dralle  H, 
Hoang-Vu C, Gimm O, Marsh DJ, Morreau H and Teh 
BT: HRPT2 mutations are associated with malignancy in 
sporadic parathyroid tumours. J Med Genet 40, 657-663 
(2003)
９） Cavaco BM, Guerra L, Bradley KJ, Carvalho D, Harding 
B, Oliveira A, Santos MA, Sobrinho LG, Thakker RV 
and Leite V: Hyperparathyroidism-jaw tumor syndrome 
in Roma families from Portugal is due to a founder 
mutation of the HRPT2 gene. J Clin Endocrinol Metab 
89, 1747-1752 (2004)
10） Cetani F, Pardi E, Borsari S, Viacava P, Dipollina 
G, Cianferotti L, Ambrogini, E, Gazzerro E, Colussi 
G, Berti P, Miccoli P, Pinchera A and Marcocci C: 
Genetic analyses of the HRPT2 gene in primary 
hyperparathyroidism: germline and somatic mutations 
in familial and sporadic parathyroid tumors. J Clin 
Endocrinol Metab 89, 5583-5591 (2004) 
11） Bradley KJ, Cavaco BM, Bowl MR, Harding B, Young 
A and Thakker RV: Utilisation of a cryptic non-canonical 
donor splice site of the gene encoding PARAFIBROMIN is 
associated with familial isolated primary hyperparathyroidism. 
J Med Genet 42, e51 (2005)
12） Moon SD, Park JH, Kim EM, Kim JH, Han JH, Yoo S 
J, Yoon KH, Kang MI, Lee KW, Son HY, Kang SK, Oh 
SJ, Kim KM, Yoon SJ, Park JG, Kim IJ, Kang HC, Hong 
SW, Kim KR and Cha BY: A novel IVS2-1G>A mutation 
causes aberrant splicing of the HRPT2 gene in a family 
with hyperparathyroidism-jaw tumor syndrome. J Clin 
Endocrinol Metab 90, 878-883 (2005)
13） Shattuck TM, Välimäki S, Obara T, Gaz RD, Clark OH, 
Shoback D, Wierman ME, Tojo K, Robbins CM, Carpten 
JD, Farnebo LO, Larsson C and Arnold A: Somatic 
and germ-line mutations of HRPT2 gene in sporadic 
parathyroid carcinoma. N Engl J Med 349, 1722-1729 
(2003)
14） Mizusawa N, Uchino S, Iwata T, Tsuyuguchi M, Suzuki 
Y, Mizukoshi T, Yamashita Y, Sakurai A, Suzuki S, 
Beniko M, Tahara H, Fujisawa M, Kamata N, Fujisawa K, 
Yashiro T, Nagao D, Golam HM, Sano T, Noguchi S and 
Yoshimoto K: Genetic analysis in patients with familial 
isolated hyperparathyroidism and hyperparathyroidism-
330 四国歯誌　第21巻第２号　2009 副甲状腺機能亢進症－顎腫瘍症候群の原因遺伝子産物パラフィブロミン（岩田） 331
jaw tumour syndrome. Clin Endoclinol 65: 9-16 (2006)
15） Hahn MA and Marsh DJ: Identification of a functional 
bipartite nuclear localization signal in the tumor 
suppressor parafibromin. Oncogene 24, 6241-6248 
(2005)
16） Bradley KJ, Bowl MR, Williams SE, Ahmad BN, 
Partridge CJ, Patmanidi AL, Kennedy AM, Loh NY 
and Thakker RV: Parafibromin is a nuclear protein with 
a functional monopartite nuclear localization signal. 
Oncogene 26, 1213-1221 (2007)
17） Rozenblatt-Rosen O, Hughes CM, Nannepaga SJ, 
Shanmugam KS, Copeland TD, Guszczynski T, Resau JH 
and Meyerson M: The parafibromin tumour suppressor 
protein is part of a human Paf1 complex. Mol Cell Biol 
25, 612-620 (2005)
18） Woodard GE, Lin L, Zhang JH, Agarwal SK, Marx 
SJ and Simonds WF: Parafibromin, product of the 
hyperparathyroidism-jaw tumor syndrome gene HRPT2, 
regulates cyclin D1/PRAD1 expression. Oncogene 24, 
1272-1276 (2004)
19） Agarwal  SK,  S imonds  WF and  Marx  SJ :  The  
parafibromin tumor suppressor protein interacts with 
actin-binding proteins actinin-2 and actinin-3. Mol 
Cancer 7, 65 (2008)
20） Shi X, Finkelstein A, Wolf AJ, Wade PA, Burton ZF and 
Jaehning JA: Paf1p, an RNA polymerase II-associated 
factor in Saccharomyces cerevisiae, may have both 
positive and negative roles in transcription. Mol Cell Biol 
16, 669-676 (1996)
21） Krogan NJ, Kim M, Ahn SH, Zhong G, Kobor MS, 
Cagney G, Emili A, Shilatifard A, Buratowski S and 
Greenblatt JF: RNA polymerase II elongation factors 
of Saccharomyces cerevisiae: a targeted proteomics 
approach. Mol Cell Biol 22, 6979-6992 (2002)
22） Mueller CL and Jaehning JA: Ctr9, Rtf1, and Leo1 are 
components of the Paf1/RNA polymerase II complex. 
Mol Cell Biol 22, 1971-1980 (2002)
23） S to l inski  LA,  Eisenmann DM and Arndt  KM: 
Identification of RTF1, a novel gene important for 
TATA site selection by TATA box-binding protein in 
Saccharomyces cerevisiae. Mol Cell Biol 17, 4490-4500 
(1997)
24） Costa PJ and Arndt KM: Synthetic lethal interactions 
suggest a role for the Saccharomyces cerevisiae Rtf1 
protein in transcription elongation. Genetics 156, 
535-547 (2000).
25） Squazzo SL, Costa PJ, Lindstorm DL, Kumer KE, Simic 
R, Jennings JL, Link AJ, Amdt KM and Hartzog GA: 
The Paf1 complex physically and functionally associates 
with transcription elongation factors in vivo. EMBO J 21, 
1764-1774 (2002)
26） Ng HH, Robert F, Young RA and Struhl K: Targeted 
recruitment of Set1 histone methylase by elongating 
Pol II provides a localized mark and memory of recent 
transcriptional activity. Mol Cell 11, 709-719 (2003)
27） Wood A, Schneider J, Dover J, Johnston M and 
Shilatifard A: The Paf1 complex is essential for histone 
monoubiquitination by the Rad6-Bre1 complex, which 
signals for histone methylation by COMPASS and Dot1p. 
J Biol Chem 278, 34739-34742 (2003)
28） Wood A, Schneider J, Dover J, Johnston M and 
Shilatifard A: The Bur1/Bur2 complex is required for 
histone H2B monoubiquitination by Rad6/Bre1 and 
histone methylation by COMPASS. Mol Cell 20, 589-599 
(2005)
29） Dover J, Schneider J, Tawiah-Boateng MA, Wood A, 
Dean K, Johnston M and Shilatifard A: Methylation 
of histone H3 by COMPASS requires ubiquitination 
o f  h i s t o n e  H2B  b y  R a d6 .  J  B i o l  C h e m  277 ,  
28368-28371(2002)
30） Krogan NJ, Dover J, Wood A, Schneider J, Heidt J, 
Boateng MA, Dean K, Ryan OW, Golshani A, Johnston 
M, Greenblatt JF and Shilatifard A: The Paf1 complex 
is required for histone H3 methylation by COMPASS 
and Dot1p: linking transcriptional elongation to histone 
methylation. Mol Cell 11, 721-729 (2003)
31） Krogan NJ, Kim M, Tong A, Golshani A, Cagney 
G, Canadien V, Richards DP, Beattie BK, Emili A, 
Boone C, Shilatifard A, Buratowski S and Greenblatt J: 
Methylation of histone H3 by Set2 in Saccharomyces 
cerevisiae is linked to transcriptional elongation by RNA 
polymerase II. Mol Cell Biol 23, 4207-4218 (2003)
32） Belotserkovskaya R, Oh S, Bondarenko VA, Orphanides 
G, Studitsky VM and Reinberg D: FACT facilitates 
transcription-dependent nucleosome alteration. Science 
301, 1090-1093 (2003)
33） Mueller CL, Porter SE, Hoffman MG and Jaehning JA: 
The Paf1 complex has functions independent of actively 
transcribing RNA polymerase II. Mol Cell 14, 447-456 
(2004)
34） Porter SE, Washburn TM, Chang M and Jaehning JA: 
The yeast pafl-RNA polymerase II complex is required 
for full expression of a subset of cell cycle-regulated 
genes. Eukaryot Cell 1, 830-842 (2002)
35） Zhu B, Mandal SS, Pham AD, Zheng Y, Erdjument-
Bromage H, Batra SK, Tempst P and Reinberg D: The 
human PAF complex coordinates transcription with 
events downstream of RNA synthesis. Genes Dev 19, 
1668-1673 (2005)
36） Komarnitsky P, Cho EJ and Buratowski S: Different 
332 四国歯誌　第21巻第２号　2009
phosphorylated forms of RNA polymerase II and 
associated mRNA processing factors during transcription. 
Genes Dev 14, 2452-2460 (2000)
37） Pavri R, Zhu B, Li G, Trojer P, Mandal S, Shilatifard 
A and Reinberg D: Histone H2B Monoubiquitination 
functions cooperatively with FACT to regulate elongation 
by RNA polymerase II. Cell 125, 703-717 (2006)
38） Lin L, Zhang JH, Panicker LM and Simonds WF: The 
parafibromin tumor suppressor protein inhibits cell 
proliferation by repression of the c-myc proto-oncogene. 
Proc Natl Acad Sci USA 105, 17420-17425 (2008)
39） Iwata T, Mizusawa N, Taketani Y, Itakura M and 
Yoshimoto K: Parafibromin tumor suppressor enhances 
cell growth in the cells expressing SV40 large T antigen. 
Oncogene 26, 6176-6183 (2007)
40） Rowland BD and Peeper DS: KLF4, p21 and context-
dependent opposing forces in cancer. Nat Rev Cancer 6, 
293-303 (2006)
41） Yokoyama A, Somervaille TCP, Smith K S, Rosenblatt-
Rosen O, Meyerson M and Cleary ML: The menin tumor 
suppressor protein is an essential oncogenic cofactor 
for MLL-associated leukemogenesis. Cell 123, 207-218 
(2005) 
42） Parada LA, Hallén M, Tranberg KG, Hägerstrand I, 
Bondeson L, Mitelman F and Johansson B: Frequent 
rearragements of chromosomes 1, 7, and 8 in primary 
liver cancer. Genes Chromosomes Cancer 23, 26-35 
(1998)
43） Stange D E, Radlwimmer B, Schubert F, Traub F, Pich 
A, Toedt G, Mendrzyk F, Lehmann U, Eils R, Kreipe H 
and Lichter P: High-resolution genomic profiling reveals 
association of chromosomal aberrations on 1q and 16p 
with histologic and genetic subgroups of invasive breast 
cancer. Clin Cancer Res 12, 345-352 (2006)
44） Korshunov A, Sycheva R, Gorelyshev S and Golanov 
A. Clinical utility of fluorescence in situ hybridization 
(FISH) in non-brainstem glioblastomas of childhood. 
Mod Pathol 18, 1258-1263 (2005)
45） Chang MC, Chang YT, Tien YW, Sun CT, Wu MS and 
Lin JT: Distinct chromosomal aberrations of ampulla 
of Vater and pancreatic head cancers detected by laser 
capture microdissection and comparative genomic 
hybridization. Oncol Rep 14, 867-872 (2005)
46） Mosimann C, Hausmann G, and Basler K: Parafibromin/
Hyrax activates Wnt/Wg target gene transcription by 
direct association with β-catenin/armadillo. Cell 125, 
327-341 (2006)
47） Moniaux N, Nemos C, Schmied BM, Chauhan SC, Deb 
S, Morikane K, Choudhury A, Vanlith M, Sutherlin M, 
Sikela JM, Hollingsworth MA and Batra SK: The human 
homologue of the RNA polymerase II-associated factor 
1 (hPaf1), localized on the 19q13 amplicon, is associated 
with tumorigenesis. Oncogene 25, 3247-3257 (2006)
48） Wang P, Bowl MR, Bender S, Peng J, Farber L, Chen J, 
Ali A, Zhang Z, Alberts AS, Thakker RV, Shilatifard A, 
Williams BO and Teh BT: Parafibromin, a component of 
the human PAF complex, regulates growth factors and 
is required for embryonic development and survival in 
adult mice. Mol Cell Biol 28, 2930-2940 (2008)
